Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)

ClinicalTrials.gov ID: NCT02794155

Public ClinicalTrials.gov record NCT02794155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2b, Multicenter, Randomized, Double Blind, Titration Trial for Efficacy and Safety of HDV Insulin Lispro in Combination With a Basal Insulin Versus Insulin Lispro in Combination With a Basal Insulin in Patients With Type 1 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This will be a Phase 2b, multicenter, randomized, double blind, titration clinical study, evaluating the efficacy and safety in the HDV Insulin Lispro Group versus Insulin Lispro Group in patients with type 1 diabetes over a 26 week treatment period. The patients will be randomized using a centrally allocated randomization scheme to 1 of the 2 treatment arms in an overall 2:1 scheme (HDV Insulin Lispro: Insulin Lispro). Both arms will receive the randomized treatment in combination with glargine or detemir. Goal to demonstrate that the efficacy of HDV insulin lispro administered in combination with a basal insulin (HDV Insulin Lispro group) is non-inferior to insulin lispro in combination with a basal insulin (Insulin Lispro group), in effects on glycated hemoglobin (HbA1c) in patients with type 1 diabetes. If non-inferiority is demonstrated, confirm that HDV insulin lispro in combination with a basal insulin (HDV Insulin Lispro group) is superior to insulin lispro in combination with a basal insulin (Insulin Lispro group), in effects on HbA1c in patients with type 1 diabetes (≥ 0.4% decrease in HbA1c).

Study identification

NCT ID
NCT02794155
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Diasome Pharmaceuticals
Industry
Enrollment
157 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2016
Primary completion
Apr 27, 2018
Completion
Jun 14, 2018
Last update posted
Jul 30, 2018

2016 – 2018

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Hope & Wellness Clinical Trials, Inc. Corona California 92882
National Research Institute Los Angeles California 90057
California Medical Research Associates Inc. Northridge California 91324
Bay Area Clinical Research San Carlos California 94070
Mills-Peninsula Health Services San Mateo California 94401
Orange County Research Center Tustin California 92780
Creekside Endocrine Associates, PC Denver Colorado 80209
Advanced Pharma CR, LLC Miami Florida 33147
Ormond Medical Arts Pharmaceutical Research Center Ormond Beach Florida 32174
Progressive Medical Research Port Orange Florida 32127
Atlanta Diabetes Associates Atlanta Georgia 30318
Endocrine Research Solutions, Inc. Roswell Georgia 30076
Rocky Mountain Diabetes & Osteoporosis Center, PA Idaho Falls Idaho 83404
Associates in Endocrinology Elgin Illinois 60124
University of Massachusetts Memorial Hospital Worcester Massachusetts 01655
Desert Endocrinology Clinical Research Center Henderson Nevada 89052
SUNY Upstate Medical University Syracuse New York 13210
LION Research Norman Oklahoma 73072
Endocrine and Psychiatry Center Houston Texas 77095
Clinical Trials of Texas, Inc. San Antonio Texas 78229
Rainier Clinical Research Center, Inc. Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02794155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2018 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02794155 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →